Allinaire Therapeutics is developing novel therapeutics for Pulmonary Diseases
Allinaire Therapeutics aims to develop novel therapeutics for Chronic Obstructive Pulmonary Disease (COPD) and other pulmonary diseases. The technology is based on the discovery by scientific founders Irina Petrache, MD, and Matthias Clauss, PhD of a novel therapeutic target that plays a central role in the development and progression of lung disease.
Drs. Petrache and Clauss have demonstrated that a therapeutic antibody against this target has a strong potential as a disease - modifying treatment to slow the progression of COPD.
COPD is a very common disease that represents a large unmet global need. By 2020, it is estimated that COPD will be the third leading cause of death. This disease is characterized by inflammation and progressive destruction of lung tissue, leading to difficulty in breathing. Allinaire Therapeutics aims to address this unmet medical need and transform the treatment of lung diseases.
Allinaire Therapeutics, LLC has a standard overhead rate of 40%. Allinaire Therapeutics may alter this policy at any time.